Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tiziana Life Sciences Ltd - Common Shares (NQ:TLSA)

2.385 +0.095 (+4.15%)
Streaming Delayed Price Updated: 2:23 PM EDT, Aug 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 293,400
Open 2.320
Bid (Size) 2.370 (10)
Ask (Size) 2.400 (27)
Prev. Close 2.290
Today's Range 2.201 - 2.460
52wk Range 0.6302 - 2.600
Shares Outstanding 194,612,289
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Lucid Is Now Shipping Adapters That Let Customers Access Elon Musk-Led Tesla's Supercharger Network
Lucid ships adapters for Air Sedan allowing owners to access over 23,500 Tesla Supercharging stations across the U.S. 
Via Benzinga
Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient
From Tiziana Life Sciences Ltd.
Via GlobeNewswire

Performance

YTD
+250.3%
+250.3%
1 Month
+55.9%
+55.9%
3 Month
+59.0%
+59.0%
6 Month
+252.9%
+252.9%
1 Year
+133.8%
+133.8%

More News

Read More
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences to Present at the Bio International Convention
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Uber Stock Ready to Ride Higher on Waymo Partnership
Via MarketBeat
Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Purchase of Shares by Chairman
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences to Present at the 37th Annual Roth Conference
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week
Via Stocktwits
Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC
From Tiziana Life Sciences Ltd.
Via GlobeNewswire

Frequently Asked Questions

Is Tiziana Life Sciences Ltd - Common Shares publicly traded?
Yes, Tiziana Life Sciences Ltd - Common Shares is publicly traded.
What exchange does Tiziana Life Sciences Ltd - Common Shares trade on?
Tiziana Life Sciences Ltd - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Tiziana Life Sciences Ltd - Common Shares?
The ticker symbol for Tiziana Life Sciences Ltd - Common Shares is TLSA on the Nasdaq Stock Market
What is the current price of Tiziana Life Sciences Ltd - Common Shares?
The current price of Tiziana Life Sciences Ltd - Common Shares is 2.385
When was Tiziana Life Sciences Ltd - Common Shares last traded?
The last trade of Tiziana Life Sciences Ltd - Common Shares was at 08/06/25 02:23 PM ET
What is the market capitalization of Tiziana Life Sciences Ltd - Common Shares?
The market capitalization of Tiziana Life Sciences Ltd - Common Shares is 464.15M
How many shares of Tiziana Life Sciences Ltd - Common Shares are outstanding?
Tiziana Life Sciences Ltd - Common Shares has 464M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.